Claims for Patent: 12,156,917

Summary for Patent: 12,156,917

Title:	CNP prodrugs with carrier attachment at the ring moiety
Abstract:	The present invention relates to CNP prodrugs in which the carrier is covalently and reversibly attached to the ring moiety of a CNP moiety, to pharmaceutical compositions comprising such CNP prodrugs, to their uses and to methods of treating diseases that can be treated with the CNP prodrugs of the present invention.
Inventor(s):	Harald Rau, Ulrich Hersel, Felix Cleemann, Kennett Sprogøe
Assignee:	Ascendis Pharma Endocrinology Division AS
Application Number:	US17/842,436
Patent Claims:	1. A method of treating achondroplasia, hypochondroplasia, short stature, Noonan syndrome or short stature homeobox-containing gene (SHOX) deficiency in a mammalian patient in need thereof, comprising the step of administering to said patient a therapeutically effective amount of a C-type natriuretic peptide (CNP) prodrug or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition comprising a CNP prodrug or a pharmaceutically acceptable salt thereof and at least one excipient, wherein the CNP prodrug or pharmaceutically acceptable salt thereof comprises a CNP moiety -D comprising a ring moiety having the sequence of SEQ ID NO:96; and a carrier moiety -Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to a side chain of an amino acid residue of said ring moiety of -D or to the backbone of said ring moiety of -D; and wherein -L2- is a chemical bond or a spacer. 2. The method of claim 1, wherein -L1- is covalently and reversibly conjugated to the side chain of an amino acid residue of the ring moiety of -D. 3. The method of claim 1, wherein the amino acid residue of the ring moiety of -D to which -L1- is conjugated is selected from the group consisting of lysine, serine, aspartic acid, and arginine. 4. The method of claim 3, wherein the amino acid residue of the ring moiety of -D to which -L1- is conjugated is lysine. 5. The method of claim 1, wherein -D has the sequence of SEQ ID NO:24. 6. The method of claim 1, wherein -D has the sequence of SEQ ID NO:24 and -L1- is conjugated to lysine at position 26. 7. The method of claim 1, wherein -L1- is of formula (II): wherein the dashed line indicates attachment to a nitrogen of an amino acid side chain of the ring moiety of the CNP moiety by forming an amide bond; -X- is —C(R4R4a)—, -N(R4)—, —O—, —C(R4R4a)—C(R5R5a)—, -C(R5R5a)—C(R4R4a)—, —C(R4R4a)—N(R6)—, —N(R6)—(R4R4a), —C(R4R4a)—O—, —O—C(R4R4a)—, or —C(R7R7a); X1 is C, or S(O); -X2- is -C(R8R8a)—, or -C(R8R8a)—C(R9R9a)—; ═X3 is ═O, ═S, or ═N-CN; —R1, —R1a, —R2, —R2a, —R4, —R4a, —R5, —R5a, —R6, —R8, —R8a, —R9, —R9a are independently selected from the group consisting of -H; and C1-6 alkyl; —R3, —R3a are independently selected from the group consisting of —H, and C1-6 alkyl, provided that in case one of —R3, —R3a or both are other than -H they are connected to the N atom to which they are attached through a sp3-hybridized carbon atom; —R7 is -N(R10R10a), or -NR10-(C═O)—R11; —R7a, —R10, —R10a, —R11 are independently of each other -H, or C1-6 alkyl; optionally, one or more of the pairs —R1a/—R4a, —R1a/—R5a, —R1a/—R7a, —R4a/—R5a, —R8a/—R9a form a chemical bond; optionally, one or more of the pairs —R1/—R1a, —R2/—R2a, —R4/—R4a, —R5/—R5a, —R8/—R8a, —R9/—R9a are joined together with the atom to which they are attached to form a C3-10 cycloalkyl; or 3- to 10-membered heterocyclyl; optionally, one or more of the pairs —R1/—R4, —R1/—R5, —R1/—R6, —R1/—R7a, —R4/R5, —R4/—R6, —R8/—R9, —R2/—R3 are joined together with the atoms to which they are attached to form a ring A; optionally, —R3/—R3a are joined together with the nitrogen atom to which they are attached to form a 3- to 10-membered heterocycle; A is selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, and 8- to 11-membered heterobicyclyl; and wherein -L1- is substituted with -L2-Z, provided that the hydrogen marked with the asterisk in formula (II) is not replaced by -L2-Z. 8. The method of claim 1, wherein -L2- is selected from the group consisting of -T-, —C(O)O—, —O—, —C(O)—, —C(O)N(Ry1)—, —S(O)2N(Ry1)—, —S(O)N(Ry1)—, —S(O)2—, -S(O)—, -N(Ry1)S(O)2N(Ry1a)—, -S—, -N(Ry1)—, -OC(ORy1)(Ry1a)—, -N(Ry1)C(O)N(Ry1a)—, —OC(O)N(Ry1)—, C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein -T-, C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally substituted with one or more —R2, which are the same or different and wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, —C(O)O—, —O—, —C(C)—, —C(O)N(Ry3)—, —S(O)2N(Ry3)—, —S(O)N(Ry3)—, —S(O)2—, —S(O)—, —N(Ry3)S(O)2N(Ry3a)—, —S—, —N(Ry3)—, —OC(ORy3)(Ry3a)—, —N(Ry3)C(O)N(Ry3a)—, and —OC(O))N(Ry3)—; —Ry1 and —Ry1a are independently of each other selected from the group consisting of —H, -T, C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein -T, C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally substituted with one or more —Ry2, which are the same or different, and wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, —C(O)O—, —O—, —C(O)—, —C(O)N(Ry4)—, —S(O)2N(Ry4)—, —S(O)N(Ry4a)—, —S(O)2—, —S(O)—, —N(Ry4)O)2N(Ry4a)—, —S—, —N(Ry4)—, —OC(OR4)(Ry4a)—, —N(Ry4)C(O)N(Ry4a)—, and —OC(O)N(Ry4)—; each T is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8- to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl; wherein each T is independently optionally substituted with one or more —Ry2, which are the same or different; each —Ry2 is independently selected from the group consisting of halogen, —CN, oxo (═O), —COORy5, -ORy5, —C(O)Ry5, —C(O)N(R5Ry5a), —S(O)2N(Ry5R5ya), —S(O)N(Ry5Ry5a), —S(O)2Ry5, —S(O)Ry5, —N(Ry5)S(O)2N(R5yaRy5b), —SRy5, —N(Ry5Ry5a), —NO2, —OC(O)Ry5N, —N(Ry5)C(O)Ry5a, —N(Ry5)S(O)2Ry5a, —N(Ry5)S(O)Ry5a, -N(Ry5)C(O)ORy5a, —N(Ry5)C(O)N(Ry5aRy5b), —OC(O)N(Ry5Ry5a), and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; and each —Ry3, —Ry3a, —Ry4, —Ry4a, —R5, —Ry5a and —Ry5b is independently selected from the group consisting of -H, and C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different. 9. The method of claim 1, wherein —Z is a branched polymer. 10. The method of claim 9, wherein the branched moiety —Z has a molecular weight of 10 kDa to 80 kDa. 11. The method of claim 1, wherein —Z comprises a moiety of formula (a): wherein the dashed line indicates attachment to -L2- or to the remainder of -Z when -L2- is a chemical bond; BPa is a branching point selected from the group consisting of -N<, —CR< and >C<; —R is selected from the group consisting of —H and C1-6 alkyl; a is 0 if BPa is -N< or —CR< and a is 1 if BPa is >C<; —Sa, —Sa′—, —Sa″ and —Sa′″- are independently of each other a chemical bond or are selected from the group consisting of C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally substituted with one or more —R1, which are the same or different and wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, —C(O)O—, —O—, —C(O)—, —C(O)N(R2)—, —S(O)2N(R2)—, —S(O)N(R2)—, —S(O)2—, —S(O)—, —N(R2)S(O)2N(R2a)—, —S—, —N(R2)—, —OC(OR2)(R2a)—, —N(R2)C(O)N(R2a)—, and —OC(O)N(R2)—; each -T- is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8- to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl; wherein each -T- is independently optionally substituted with one or more —R1, which are the same or different; each —R1 is independently selected from the group consisting of halogen, —CN, oxo (═O), —COOR3, —OR3, —C(O)R3, —C(O)N(R3R3a), —S(O)N(R3R3a), —S(O)N(R3R3a), —S(O)2R3, —S(O)R3, N(R3)S(O)2N(R3aR3b), —SR3, —N(R3aR3b), —NO2, —OC(O)R3, —N(R3)C(O)R3a, —N(R3)S(O)2R3a, —N(R3)S(O)R3a, —N(R3)C(O)OR3a, —N(R3)C(O)N(R3aR3b), —OC(O)N(R3R3a), and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; each —R2, —R2a, —R3, —R3a and —R3b is independently selected from the group consisting of —H, and C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; and -Pa′, -Pa″ and -Pa′″ are independently a polymeric moiety. 12. The method of claim 1, wherein the disease is achondroplasia. 13. The method of claim 1 wherein the administering is subcutaneous.